OTCMKTS:CPMV Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis $0.53 +0.04 (+7.80%) As of 05/27/2025 11:45 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Mosaic ImmunoEngineering Stock (OTCMKTS:CPMV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPMV alerts:Sign Up Key Stats Today's Range$0.27▼$0.5350-Day Range$0.49▼$0.8452-Week Range$0.10▼$1.13Volume225 shsAverage Volume1,026 shsMarket Capitalization$3.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Read More… Mosaic ImmunoEngineering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCPMV MarketRank™: Mosaic ImmunoEngineering scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mosaic ImmunoEngineering. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mosaic ImmunoEngineering is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mosaic ImmunoEngineering is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Mosaic ImmunoEngineering's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Mosaic ImmunoEngineering has been sold short.Short Interest Ratio / Days to CoverMosaic ImmunoEngineering has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMosaic ImmunoEngineering does not currently pay a dividend.Dividend GrowthMosaic ImmunoEngineering does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Mosaic ImmunoEngineering has been sold short.Short Interest Ratio / Days to CoverMosaic ImmunoEngineering has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.7 / 5News SentimentN/A News SentimentMosaic ImmunoEngineering has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mosaic ImmunoEngineering insiders have not sold or bought any company stock.Percentage Held by Insiders80.99% of the stock of Mosaic ImmunoEngineering is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mosaic ImmunoEngineering's insider trading history. Receive CPMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mosaic ImmunoEngineering and its competitors with MarketBeat's FREE daily newsletter. Email Address CPMV Stock News HeadlinesMosaic ImmunoEngineering, Inc. (CPMV)November 17, 2024 | finance.yahoo.comMosaic Co.November 5, 2024 | wsj.comDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned. If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.May 28, 2025 | Lear Capital (Ad)Mosaic ImmunoEngineering (OTC:CPMV) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 14, 2024 | msn.comNanoparticle plant virus treatment shows promise in fighting metastatic cancers in miceMay 13, 2024 | msn.comMosaic ImmunoEngineering Inc.: Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.April 29, 2024 | finanznachrichten.deOncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.April 29, 2024 | finance.yahoo.comSee More Headlines CPMV Stock Analysis - Frequently Asked Questions How have CPMV shares performed this year? Mosaic ImmunoEngineering's stock was trading at $0.7012 on January 1st, 2025. Since then, CPMV shares have decreased by 24.7% and is now trading at $0.5280. View the best growth stocks for 2025 here. How were Mosaic ImmunoEngineering's earnings last quarter? Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) issued its quarterly earnings data on Tuesday, May, 20th. The company reported ($0.03) EPS for the quarter. How do I buy shares of Mosaic ImmunoEngineering? Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mosaic ImmunoEngineering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Applied Genetic Technologies (AGTC), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and Aeva Technologies (AEVA). Company Calendar Last Earnings5/20/2025Today5/27/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CPMV CIK836564 Webwww.ptsc.com Phone(657) 208-0890Fax760-547-2705Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.01 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,371.05% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-0.65Miscellaneous Outstanding Shares7,242,000Free Float1,377,000Market Cap$3.82 million OptionableNot Optionable Beta0.11 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (OTCMKTS:CPMV) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mosaic ImmunoEngineering, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mosaic ImmunoEngineering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.